What is Megace (megestrol acetate) used for?

What is Megace (Megestrol Acetate) Used For?

Megace (megestrol acetate) is FDA-approved specifically for treating anorexia, cachexia, or unexplained significant weight loss in patients with AIDS, and is also widely used off-label as an appetite stimulant in cancer-related anorexia and cachexia. 1

Primary FDA-Approved Indication

• AIDS-related wasting syndrome: Megestrol acetate is indicated for anorexia, cachexia, or unexplained significant weight loss in patients with acquired immunodeficiency syndrome (AIDS). 1

Off-Label Use in Cancer

• Cancer-related anorexia/cachexia: Megestrol acetate is recommended as a first-line pharmacological intervention for patients with cancer-related anorexia and weight loss, particularly when increased appetite is an important quality of life goal and life expectancy is measured in months rather than weeks. 2, 3

• Appetite stimulation efficacy: Patients receiving megestrol acetate are approximately 2.57 times more likely to experience appetite improvement and 1.55 times more likely to gain weight compared to placebo in cancer patients. 2, 3

• Minimum effective dose: The minimum efficacious dose is 160 mg/day, though the optimal dose for maximal benefit appears to be 480-800 mg/day, with no additional advantage at doses exceeding 800 mg/day. 4, 2

Historical Use in Breast Cancer

• Hormone-sensitive breast cancer: Megestrol acetate has a longstanding history in treating postmenopausal women with hormone-sensitive advanced breast cancer, particularly after aromatase inhibitor failure, though this use has declined with newer agents. 5

Mechanism of Action

• Appetite stimulation pathways: Megestrol acetate stimulates appetite through downregulation of proinflammatory cytokines (TNF-α, IL-1, IL-6) that drive cachexia, influence on the hypothalamic appetite regulation center, and potential glucocorticoid-like effects at higher doses. 3, 6

Critical Safety Considerations

Thromboembolic Risk

• Significantly increased thrombosis: Approximately 1 in 6 patients (relative risk 1.84) will develop thromboembolic phenomena, including deep vein thrombosis and pulmonary embolism. 2, 3
• Regular monitoring required: Assessment for thromboembolic phenomena is essential throughout treatment. 2, 6

Mortality Risk

• Increased death risk: Mortality risk is elevated with a relative risk of 1.42 compared to placebo, with approximately 1 in 23 patients at risk of treatment-related death. 2, 3

Quality of Weight Gain

• Adipose tissue predominance: Weight gain achieved is primarily adipose tissue rather than skeletal muscle or lean body mass, which may limit functional clinical benefit. 2, 3, 6

Endocrine Effects

• Adrenal suppression: Chronic use can cause adrenal insufficiency, Cushing's syndrome, new-onset diabetes, and exacerbation of pre-existing diabetes due to glucocorticoid-like activity. 1
• Adrenal monitoring: Adrenal function should be monitored in patients on long-term therapy, with consideration of stress-dose glucocorticoids during illness or surgery. 2, 1

Other Adverse Effects

• Edema: Occurs with a relative risk of 1.36 compared to placebo. 2, 3

Dosing Recommendations

Standard Dosing

• Starting dose: Initiate at 400-800 mg orally once daily, with 800 mg/day showing superior efficacy in clinical trials. 2
• Alternative lower starting dose: 160 mg/day is reasonable for initial treatment in routine practice, with titration to 480-800 mg/day based on response. 2
• Maximum dose: Do not exceed 800 mg/day, as higher doses provide no additional benefit and increase cost. 2

Formulation Considerations

• Liquid formulation preferred: The oral suspension is preferred over tablets as it is less expensive and more bioavailable, particularly important in cachectic patients with reduced caloric intake. 2, 7

Duration and Monitoring

• Limited duration: Duration of therapy should be limited, with regular reassessment of benefit versus risk, particularly after 12 weeks of treatment. 2, 3
• Weight monitoring: Monitor weight changes to assess response, recognizing that gains will be primarily fat rather than lean muscle. 2, 6

Alternative and Combination Approaches

Corticosteroids as Alternative

• Dexamethasone: Consider dexamethasone 2-8 mg/day as an alternative, offering similar appetite stimulation with a different toxicity profile and lower cost, though limited to short-term use (1-3 weeks maximum) due to side effects including muscle wasting, insulin resistance, and infection risk. 2
• Patient selection: Corticosteroids are preferred for patients with very short life expectancy (weeks to a couple of months), while megestrol acetate is more appropriate for those with life expectancy measured in months. 2

Combination Therapy

• Olanzapine addition: Adding olanzapine 5 mg/day to megestrol acetate increased the proportion of patients achieving ≥5% weight gain (85% vs 41%) in one trial, though this requires further validation. 2
• Multi-agent regimens: Combinations including L-carnitine, celecoxib, and antioxidants have shown improved lean body mass and quality of life in phase III trials. 2, 3

Non-Pharmacological Approaches

• Exercise programs: Resistance exercise should be considered to preserve lean body mass, as megestrol acetate alone does not prevent muscle wasting. 2
• Fish oil supplementation: Long-chain N-3 fatty acids may help stabilize or improve appetite and body weight in advanced cancer patients undergoing chemotherapy. 2

Common Pitfalls to Avoid

• Inappropriate prophylactic use: Megestrol acetate is not intended for prophylactic use to avoid weight loss; treatable causes of weight loss (malignancies, infections, gastrointestinal disorders, endocrine disease) must be sought and addressed first. 1

• Use in very short life expectancy: Avoid initiating megestrol acetate in patients with life expectancy of only weeks; corticosteroids are more appropriate in this setting. 2

• Excessive dosing: Do not exceed 800 mg/day, as higher doses provide no additional benefit. 4, 2

• Unrealistic expectations: Counsel patients that weight gain will be primarily fat, not lean muscle, to set realistic expectations about functional improvement. 2

• Pregnancy risk: Megestrol acetate is Pregnancy Category X and may cause fetal harm; women of childbearing potential must use contraception and be advised to avoid becoming pregnant. 1

• Drug interactions: Coadministration with indinavir results in significant decreases in indinavir pharmacokinetic parameters (~36% for Cmax and ~28% for AUC), requiring consideration of higher indinavir doses. 1

Contraindications and Special Populations

• History of thromboembolic disease: Use with extreme caution in patients with prior thromboembolism given the 1.84-fold increased risk. 2, 1

• Diabetic patients: Exacerbation of pre-existing diabetes with increased insulin requirements has been reported; close glucose monitoring is essential. 1

• Elderly patients: Dose selection should be cautious, starting at the low end of the dosing range, with attention to decreased renal function common in this population. 1

• Renal impairment: Megestrol acetate is substantially excreted by the kidney; the risk of toxic reactions may be greater in patients with impaired renal function. 1